Oncotelic Therapeutics Inc · OTC:OTLC
Oncotelic Therapeutics — Investor Presentation (February 2022)
13 slides from Oncotelic Therapeutics's investor presentation, Feb 9, 2022
Slide 1: OT-101 / Trabedersen
ONCOTELIC THERAPEUTICS OT-101/ Trabedersen Vuong frieu-CEO Oncotelic Therapeutics, Inc. 2/7/22 WWW.ONCOTELIC.COM
Slide 2: Antisense as Next Generation Drugs
Antisense as Next Generation Drugs Patributes | SmaliMolecules maT Inception Size Drug Discovery Success Rate Predictable PK On Target Safety Off Target Safety Risk Profile Speed of Development Manufacturing Cost Amenable to Individual Therapy ONCOTELIC THERAPEUTICS 1850s to present 200-500 Random s
Slide 3: OT-101: Drug Product - TGF-B2 Antisense
OT-101: Drug Product- TGF-B2 Antisense. * Trabedersen (OT-101) is a single-stranded phosphorothioate antisense oligodeoxynucleotide (18-mer) targeting the human TGF-B2 messenger RNA * Ready for registration trials--Over 200 patients treated across 6 clinical trials * Strong Patent protection until 2
Slide 4: Clinical Efficacy: Glioblastoma
A Tumor Volume ONCOTELIC®™ THERAPEUTICS Clinical Efficacy: Glioblastoma Treatment failure patients (recalcitrant to radiation, surgery, and chemo) Objective responses were observed among the 87 evaluable patients treated with OT-101: Best Objective Responses were: 5 CR (5.9%), 14 PR (16.5%), 28 SD (
Slide 5: Clinical Efficacy: Pancreatic Cancer
Clinical Efficacy: Pancreatic Cancer Phase 2- treatment failure pts/ recalcitrant to Whipple and chemo * Patient 1006: CR as far out as 77 mos * Patient 1022: OS of 40 months * Surgery: Whipple's procedure * Surgery: Whipple's procedure * 1st line: 5-FU/LV, Dose 425 mg/m2 * 15t line: Radiation thera
Slide 6: Clinical Efficacy: COVID
Clinical Efficacy: COVID Large surge in TGF-beta during active COVID infection An established role of TGF-beta in scarring and late stage post-COVID symptoms Strong in vitro activity against SARS-COV-2 on Vero cells Positive outcome for OT-101 in phase 2 clinical trial against COVID * h Peony euro b
Slide 7: OT-101/IL-2 Efficacy In Vivo
OT-101/IL-2 Efficacy In Vivo * Combination of TASO and IL-2 treatment showed better tumor growth inhibition of melanoma cell line (A2058) than TASO alone, IL-2 alone and Pembrolizumab alone in humanized mouse model (NSG mouse) id a. vo Vv Vv vey oe 7/6) 5)4/3/2/1 0 1]2 2 [47s] «Bel » aaa aaaeeaal ++
Slide 8: NCT04862767
NCT04862767 ¢ TASO-001 in Combination With Recombinant Interleukin-2(Aldesleukin) in Advanced or Metastatic Solid Tumor ¢ Multi-center, Open Label, Phase Ib Clinical Trial to Evaluate Safety, Tolerance and Efficacy of TASO(TGF-82 Targeting Anti-sense Oligonucleotide)-001 in Combination With Recombin
Slide 9: IL-2 complete regression patient examples
Upper panel, Fifty-six- year-old male with metastatic renal cell cancer to the liver and subcarinal lymph nodes was treated with high-dose bolus IL-2 in January 1994. Patient underwent a complete regression of all disease and remains disease-free 20 y later. Upper middle panel, Fifty-four- year-old
Slide 10: OT-101 Biomarker Program
OT-101 Biomarker Program ¢ This is a combination of mesothelioma, lung, pancreatic, melanoma, DIPG, and GPM clinical trials in collaboration with Merck combining Keytruda with OT-101. * Tumor biopsy previous to treatment and post treatment will be used to generate predictive biomarkers for tumor res
Slide 11: High TGF-B signature predicts immunotherapy resistance
Ni, Y., Soliman, A., Joehlin-Price, A. et al. High TGF-B signature predicts immunotherapy resistance in gynecologic cancer patients treated with immune checkpoint inhibition. Precis. Onc. 5, 101 (2021). D E PFS Kapan-Wler Curve based on TGFBS:ore (OV PFS Kaplan-Meier Curve based on TGFBScore Low TGF
Slide 12: Keytruda Agnostic Approval
Keytruda Agnostic Approval * OnJune 16, 2020, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co., Inc.) for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [210 mutations/megabase (m
Slide 13: Pipeline (Oncology and Virology)
ONCOTELIC THERAPEUTICS Solid Tumors OT-101+Abx Lysate? ncer Glioblastoma cv cr » > _cmapsrembso > Pediatric Melanoma > _cmpsPembro > Melanoma > SS, name a Sane Phase 1 ABio/ Clinigen RPD/Approval on Ph2 Lung Cancer/ Merck Post Infection Damages RPD/ Approval on Ph2 RPD/ Approval on Ph2 Phase 2 Pipel
Oncotelic Therapeutics — Investor Presentation (February 2022) on 6ix